An Insightful Look into the Future of WAX by Malcolm CasSelle

The Worldwide Asset eXchange (WAX) is a platform, which allows anyone to trade in virtual game assets. This shows how powerful in-game tokenizing has become. This platform has created a marketplace that allows assets transfers and fractionalizes player profits; something that was impossible before.

One of the major challenges that asset tokenization has been facing was how to ensure blockchain tokens would stay tied to an asset. However, that has now been solved by WAX, which has a multi-layer governance system in place.

This fractionalization opens up endless possibilities for collectors and fans. This new innovative ecosystem is definitely a nice snippet of what the future is going to look like.


About Malcolm CasSelle


Malcolm CasSelle is an internationally renowned entrepreneur. He currently works at tronc, Inc. where he holds the position of President of New Ventures and Chief Technology Officer. Before that, Malcolm was a Senior VP and GM in charge of Digital Media at SeaChange International. He has also led the formation of various startups in the digital world such as Xfire, Groupon’s collaboration with the Chinese Tencent, and MediaPass.

Besides that, he was an active early investor in companies such as Zynga, Facebook, and most recently in companies related to the Bitcoin. Malcolm is a great believer in Bitcoin and all other accompanying technologies such as the Blockchain. He has written quite a lot on this issue.

Amongst the most significant companies that he co-founded include NetNoir, which was amongst the first companies that AOL accepted into its Greenhouse Program. The other one was PCCW (Pacific Century CyberWorks). The company is publicly traded telco that operates out of Hong Kong. According to publicly available financial data, the company is worth over $35 billion.

Malcolm CasSelle is quite well educated and has a bachelor’s degree and master’s degree in Computer Science from MIT and Stanford respectively. Besides that, he is fluent in both Japanese and Mandarin.


Oncotarget Is Maximizing The Impact Of Scientific Research

Oncotarget is a multidisciplinary journal that publishes papers focusing on cancer research and oncology. It was created in 2010. Impact Journals publishes the journal. Mikhail Blagosklonny and Andrei V. Gudkov serve as the editors in chief of Oncotarget. The mission of Oncotarget is to avail scientific outcomes to the public. In addition, the journal aims to optimize the impact of research through insightful reviews. Oncotarget seeks to enhance quick sharing of discoveries and allow experts to work together in developing different solutions to existing problems. Moreover, the journal has been connecting various fields of biomedical science and promoting applications of primary and clinical science to fight different diseases. Check the journal at SCImago Journal & Country Rank.

Under the leadership of revered scientists, Oncotarget has managed to facilitate all researchers to contribute to the advancement of science. Its ultimate goal is to ensure that people enjoy life without disease. Because of the journal’s success, its leadership decided to incorporate other fields beyond oncology. These new areas include pathology, immunology, physiology, and endocrinology.

Notably, Oncotarget applies the Creative Common Attribution License. Authors retain ownership of the copyright for their work. However, they allow anyone to reprint, reuse, download, modify, copy, or distribute journals published on Oncotarget if they cite the original author.

Noteworthy, research involving human participants has to be approved by the institutional review board of the authors. In their work, authors must name the board. In addition, Authors must obtain informed consent from third parties before publishing any information shared by these individuals. The entire clinical investigation has to be conducted in line with the principles articulated in the declaration of Helsinki. Authors must submit a statement showing that the research was approved by either the institutional review board or ethics committee.

Research based on animal work has to be conducted according to the national and international guidelines. Reports must be written in accordance with the Weatherall report’s recommendations. When researching on non-human primates, Oncotarget requires authors to include information about animal welfare. Oncotarget, which is published by Impact Journals

Oncotarget Offers A Disciplined Method of Publishing Scientific Papers

Since 2010, Oncotarget has been a well-known platform for the submission and publication of research papers and articles about oncology and related subjects. The research papers and articles are published weekly so that anything new of importance can be observed by the medical community at large as quickly as possible.

Oncotarget was founded in 2010, and the Editors-in-Chief are Mikhail Blagosklonny and Andrei V. Gudkov, both of the Roswell Park Cancer Institute, Buffalo, NY. Well-researched studies of the latest discoveries and procedures in the oncology field have a long history of saving lives when seemingly all hope has been lost.

Some of the fields in addition to oncology that are considered appropriate for submission, due to their relevance to the study of oncology include Endocrinology, Geotarget/Aging, Cardiology, Pharmacology, Metabolism, Neuropathologic/Neuroscience, Immunology/Microbiology and Cell and Mol Biology.

Researchers and authors submit their papers and manuscripts to the Editorial Board of Oncotarget. The editors on YouTube then thoroughly read and evaluate the paper, taking into consideration the merit of the paper, its uniqueness, its accuracy, the citations used as proofs, and the overall methods used to prove the main thesis.

Care is taken to research whether or not similar subjects have been written about and whether this paper is different enough in scope and proofs to warrant a new look. The complexity of oncology on, particularly at the cellular level, leaves lots of room for expansion, yet there must be enough of a divergence to warrant a new look.

Editors work in pairs, and they must be expert in the subject in which each author submits. This peer review technique maintains the proper balance in expertise and accurate presentations, as the reviewers are well-versed on the subject matter.

Care is taken to that there is no other theme or distraction to cloud the intent and direction of the submitted item. For example, slander, opinion, political inferences, sexual orientation, racial or gender inferences, or any other distractive dialogue will not be permitted.

None of the material may be used by the editorial board for any personal use and all of the material contained in the submitted copy will be held as confidential, except with the author. This keeps the content pure and when published the medical community can be assured that the content is pristine and untainted.

Learn more about Oncotarget: